LRT Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-6,234
Closed -$317K 113
2025
Q4
$317K Sell
6,234
-14,988
-71% -$766K 0.27% 78
2025
Q3
$1.18M Buy
21,222
+14,239
+204% +$833K 0.78% 52
2025
Q2
$482K Sell
6,983
-7,354
-51% -$500K 0.29% 71
2025
Q1
$996K Buy
14,337
+10,366
+261% +$856K 0.68% 51
2024
Q4
$342K Sell
3,971
-3,196
-45% -$346K 0.27% 82
2024
Q3
$853K Buy
+7,167
New +$956K 0.79% 55
2024
Q1
Sell
-4,230
Closed -$438K 89
2023
Q4
$438K Sell
4,230
-12,894
-75% -$1.28M 0.41% 72
2023
Q3
$1.56M Sell
17,124
-9,170
-35% -$808K 1.08% 42
2023
Q2
$2.06M Buy
26,294
+9,008
+52% +$736K 1.52% 26
2023
Q1
$1.38M Sell
17,286
-35,366
-67% -$2.51M 1.03% 41
2022
Q4
$3.56M Buy
52,652
+4,798
+10% +$281K 2.06% 21
2022
Q3
$2.38M Buy
47,854
+29,110
+155% +$1.56M 1.63% 28
2022
Q2
$1.04M Sell
18,744
-33,232
-64% -$1.84M 0.79% 45
2022
Q1
$2.89M Sell
51,976
-49,224
-49% -$2.53M 1.85% 25
2021
Q4
$5.67M Buy
+101,200
New +$5.48M 4.31% 4

Other funds holding NVO

LRT Capital Management's NVO Position: Q1 2026 in Review

LRT Capital Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 6,234 shares — an estimated $317K sold.

LRT Capital Management first reported a position in NVO in Q4 2021 and held it in 15 quarters. The position peaked at $5.67M in Q4 2021. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • LRT Capital Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • LRT Capital Management sold 6,234 Novo Nordisk shares in Q1 2026, an estimated $317K.
  • LRT Capital Management first reported a position in Novo Nordisk in Q4 2021 and held it in 15 quarters.
  • LRT Capital Management's Novo Nordisk position peaked at $5.67M in Q4 2021.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on LRT Capital Management's 13F filing for Q1 2026, filed 15 May 2026.